Biotron Ltd has released a press release.
Renounceable Rights Issue
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- Updated Appendix 4C
- Agreement with C14 Consulting Group
- $1.8M R&D Rebate Received
- BIT225-012 phase 2 covid-19 clinical trial
- BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
Later from Biotron
- Prospectus
- Response to ASX Aware Query
- Supplementary Prospectus
- Response to ASX Query Letter
- Replacement Prospectus
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron